retatrutide phase 3 trial dosing schedule First data, a Triumph of Science! A Clinician's Guide to Retatrutide

Dehydration Risk Vomiting or diarrhea can cause dehydration, which exacerbates fatigue

2022 DOI: 10.1016/S0140-6736(22)02033-5 PMID: 36354040 Read on PubMed The Lancet Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Rosenstock J, Frias J, Jastreboff AM, et al

At the same time, the large number of obese patients preferred its use

These approaches are broadly consistent with guidance used for managing fatigue associated with other GLP-1 receptor agonists, as reflected in NHS and NICE resources for weight management pharmacotherapy (including NICE TA875 on semaglutide for weight management)